Consequences of rush to emergency use authorization of bamlanivimab
Am J Health Syst Pharm
.
2021 Nov 9;78(22):2086-2087.
doi: 10.1093/ajhp/zxab274.
Authors
Mia Lussier
1
,
Michelle N Meyer
2
,
Eric Wright
1
Affiliations
1
Center for Pharmacy Innovation and Outcomes, Geisinger, Forty Fort, PA, USA.
2
Center for Translational Bioethics and Health Care Policy, Geisinger, Danville, PA, USA.
PMID:
34216205
PMCID:
PMC8576440
DOI:
10.1093/ajhp/zxab274
No abstract available
Keywords:
COVID-19; EUA; bamlanivimab; coronavirus; emergency use authorization.
MeSH terms
COVID-19*
Humans
SARS-CoV-2
Grants and funding
Pfizer
Merck Sharp and Dohme
DA/NIDA NIH HHS/United States
PCORI/Patient-Centered Outcomes Research Institute/United States